Table 1 Data on patient characteristics, sample types, symptoms at collection, clades, and number of mutations found in the SARS-CoV-2 genomes isolated from COVID-19 patients.

From: Whole-genome analysis and mutation pattern of SARS-CoV-2 during first and second wave outbreak in Gwangju, Republic of Korea

Patient (age/sex)

Sample type

Symptoms at sample collection

Symptom severity

Clade/lineage

Mutations

GISAID

Nextstrain

Nucleotide

Amino acid

M/46

Nasopharynx

Coughing, chills

Mild to moderate

V

19A

7

5

M/30

Nasopharynx

Coughing, sore throat, chills

Mild to moderate

5

4

Sputum

4

3

M/30

Sputum

Febrile sensation

Mild to moderate

5

3

Nasopharynx

5

3

F/29

Nasopharynx

Sore throat, myalgia, chills

Mild to moderate

6

3

Nasopharynx

5

3

Sputum

6

3

Nasopharynx

5

3

Nasopharynx

6

3

Nasopharynx

6

4

M/68

Nasopharynx

Febrile sensation, chills, fever

Mild to moderate

GH

20C

12

6

F/53

Nasopharynx

Myalgia, fever

Mild to moderate

12

7

F/81

Nasopharynx

Coughing, rhinorrhea

Mild to moderate

16

11

M/68

Sputum

Chills, fever

Severe

20

13

M/76

Sputum

Fever, cough, dizziness, chills

Mild to moderate

14

8

M/74

Sputum

Cough, phlegm

Mild to moderate

21

9

F/51

Sputum

Sore throat

Mild to moderate

20

8

F/37

Nasopharynx

Asymptomatic

Asymptomatic

24

15

M/83

Nasopharynx

Hypotension, low oxygen saturation

Critical/fatal

19

7

Nasopharynx

19

7

Cell supernatant

20

9

Cell supernatant

20

8

Plasma

20A

17

9

Nasopharynx

20C

17

7

Sputum

17

9

M/82

Nasopharynx

Fever

Mild to moderate

22

12

Nasopharynx

22

12

F/93

Cell supernatant, nasopharynx

Myalgia

Mild to moderate

15

10

F/66

Cell supernatant, sputum

Dyspnea

Mild to moderate

22

10

F/78

Cell supernatant, sputum

Sore throat, myalgia, chills

Mild to moderate

GH

20C

22

9

F/87

Cell supernatant, nasopharynx

Hypotension, low oxygen saturation

Critical/fatal

20

7